Santen Pharmaceutical Co., Ltd. announced consolidated financial results for the nine months ended December 31, 2019. For the period, on IFRS basis, the company reported revenue of JPY 182,326 million against JPY 173,210 million for the same period a year ago. Operating profit was JPY 28,942 million against JPY 33,657 million for the same period a year ago. Net profit for the period was JPY 20,278 million against JPY 23,367 million for the same period a year ago. Basic earnings per share were JPY 50.86 per share against JPY 57.44 per share for the same period a year ago. Diluted earnings per share were JPY 50.71 per share against JPY 57.26 per share for the same period a year ago.

For the period, on core basis, the company reported revenue of JPY 182,326 million against JPY 173,210 million for the same period a year ago. Operating profit was JPY 37,980 million against JPY 35,082 million for the same period a year ago. Net profit for the period was JPY 27,206 million against JPY 25,655 million for the same period a year ago. Basic earnings per share were JPY 68.22 per share against JPY 63.06 per share for the same period a year ago. Diluted earnings per share were JPY 68.02 per share against JPY 62.87 per share for the same period a year ago.

For the year ending March 31, 2020, on IFRS basis, the company expects revenue to be JPY 248,000 million, operating profit to be JPY 34,500 million, net profit for the year to be JPY 23,200 million, basic earnings per share to be JPY 58.98 per share.

For the year ending March 31, 2020, on core basis, the company expects revenue to be JPY 248,000 million, operating profit to be JPY 51,000 million, net profit for the year to be JPY 37,700 million, basic earnings per share to be JPY 95.29 per share.